Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico

Herbert L. DuPont, Charles D. Ericsson, John J. Mathewson, F. J. De La Cabada, Dennis A. Conrad

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Objective.-To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea. Design.-One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy. Setting.-We studied US students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting. Main Outcome Measure.-We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo. Results.-Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P<<.01); for those with enterotoxigenic Escherichia coli diarrhea, by 50 hours (P<.01); for those with shigellosis, by 90 hours (P, not significant [small sample size]); for all bacterial agents, by 57 hours (P<<.01). Clinical failures during the 5 days of therapy were seen in six patients (6%) receiving aztreonam and 25 (27%) receiving placebo (P<.01). Pathogen eradication occurred in 95% of those receiving aztreonam and in 70% of those receiving the placebo (<.01). All bacterial enteropathogens were susceptible in vitro to aztreonam. The drug was well tolerated. Conclusions.-Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.

Original languageEnglish (US)
Pages (from-to)1932-1935
Number of pages4
JournalJournal of the American Medical Association
Volume267
Issue number14
StatePublished - 1992
Externally publishedYes

Fingerprint

Aztreonam
Mexico
Diarrhea
Placebos
Therapeutics
Students
Bacillary Dysentery
Enterotoxigenic Escherichia coli
Treatment Failure
Sample Size
Outcome Assessment (Health Care)
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

DuPont, H. L., Ericsson, C. D., Mathewson, J. J., De La Cabada, F. J., & Conrad, D. A. (1992). Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. Journal of the American Medical Association, 267(14), 1932-1935.

Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. / DuPont, Herbert L.; Ericsson, Charles D.; Mathewson, John J.; De La Cabada, F. J.; Conrad, Dennis A.

In: Journal of the American Medical Association, Vol. 267, No. 14, 1992, p. 1932-1935.

Research output: Contribution to journalArticle

DuPont, HL, Ericsson, CD, Mathewson, JJ, De La Cabada, FJ & Conrad, DA 1992, 'Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico', Journal of the American Medical Association, vol. 267, no. 14, pp. 1932-1935.
DuPont, Herbert L. ; Ericsson, Charles D. ; Mathewson, John J. ; De La Cabada, F. J. ; Conrad, Dennis A. / Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. In: Journal of the American Medical Association. 1992 ; Vol. 267, No. 14. pp. 1932-1935.
@article{fb25df6c0c374110bf2ed84c3631ef56,
title = "Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico",
abstract = "Objective.-To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea. Design.-One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy. Setting.-We studied US students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting. Main Outcome Measure.-We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo. Results.-Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P<<.01); for those with enterotoxigenic Escherichia coli diarrhea, by 50 hours (P<.01); for those with shigellosis, by 90 hours (P, not significant [small sample size]); for all bacterial agents, by 57 hours (P<<.01). Clinical failures during the 5 days of therapy were seen in six patients (6{\%}) receiving aztreonam and 25 (27{\%}) receiving placebo (P<.01). Pathogen eradication occurred in 95{\%} of those receiving aztreonam and in 70{\%} of those receiving the placebo (<.01). All bacterial enteropathogens were susceptible in vitro to aztreonam. The drug was well tolerated. Conclusions.-Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.",
author = "DuPont, {Herbert L.} and Ericsson, {Charles D.} and Mathewson, {John J.} and {De La Cabada}, {F. J.} and Conrad, {Dennis A.}",
year = "1992",
language = "English (US)",
volume = "267",
pages = "1932--1935",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico

AU - DuPont, Herbert L.

AU - Ericsson, Charles D.

AU - Mathewson, John J.

AU - De La Cabada, F. J.

AU - Conrad, Dennis A.

PY - 1992

Y1 - 1992

N2 - Objective.-To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea. Design.-One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy. Setting.-We studied US students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting. Main Outcome Measure.-We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo. Results.-Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P<<.01); for those with enterotoxigenic Escherichia coli diarrhea, by 50 hours (P<.01); for those with shigellosis, by 90 hours (P, not significant [small sample size]); for all bacterial agents, by 57 hours (P<<.01). Clinical failures during the 5 days of therapy were seen in six patients (6%) receiving aztreonam and 25 (27%) receiving placebo (P<.01). Pathogen eradication occurred in 95% of those receiving aztreonam and in 70% of those receiving the placebo (<.01). All bacterial enteropathogens were susceptible in vitro to aztreonam. The drug was well tolerated. Conclusions.-Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.

AB - Objective.-To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea. Design.-One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy. Setting.-We studied US students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting. Main Outcome Measure.-We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo. Results.-Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P<<.01); for those with enterotoxigenic Escherichia coli diarrhea, by 50 hours (P<.01); for those with shigellosis, by 90 hours (P, not significant [small sample size]); for all bacterial agents, by 57 hours (P<<.01). Clinical failures during the 5 days of therapy were seen in six patients (6%) receiving aztreonam and 25 (27%) receiving placebo (P<.01). Pathogen eradication occurred in 95% of those receiving aztreonam and in 70% of those receiving the placebo (<.01). All bacterial enteropathogens were susceptible in vitro to aztreonam. The drug was well tolerated. Conclusions.-Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.

UR - http://www.scopus.com/inward/record.url?scp=0026571980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026571980&partnerID=8YFLogxK

M3 - Article

C2 - 1548825

AN - SCOPUS:0026571980

VL - 267

SP - 1932

EP - 1935

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 14

ER -